Sa1935 Population Pharmacokinetic Modeling Analysis of Golimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Omoniyi J. Adedokun(Western University), William J. Sandborn(University of San Diego), Brian G. Feagan(Western University), Colleen Marano(Johnson & Johnson (United States)), Sam Liao, Hugh M. Davis(South College), Zhenhua Xu(Hebei Medical University), Walter Reinisch(Medical University of Vienna), Rick Strauss, Jewel Johanns(Johnson & Johnson (United States)), Hongyan Zhang(Northwest A&F University)
Cited by 7
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k